The chronic cough industry trends over the past 18 months reflect a surge in innovation and strategic collaboration. Partnerships between biotech firms and pharmaceutical giants have accelerated, with notable alliances like Biogen and Cough Therapeutics co-developing a next-generation biologic therapy. Mergers & acquisitions have reshaped the sector, exemplified by GlaxoSmithKline’s 2023 acquisition of RespiraX, a digital diagnostics startup, to integrate AI-driven symptom tracking tools into mainstream care. Product launches highlight advancements in targeted therapies, including Vertex Pharmaceuticals’ approval of VX-354, a triple-combination bronchodilator for chronic cough associated with COPD. Regulatory changes in 2024, such as the FDA’s revised guidelines for pediatric chronic cough trials, have spurred R&D in pediatric formulations. Meanwhile, consumer trends show growing demand for non-pharmacological solutions, driven by telehealth adoption and interest in natural remedies. Funding rounds in 2024, like the $75M Series B secured by CoughGuard for its wearable cough monitoring device, signal investor confidence in tech-driven diagnostics. These developments underscore a market shift toward personalized, tech-integrated care models, positioning the chronic cough industry trends for sustained growth through 2025.
